- Home
- LNZA vs CRVO Comparison
LNZA vs CRVO Comparison
Compare LNZA & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- CRVO
- Stock Information
- Founded
- LNZA 2005
- CRVO 2001
- Country
- LNZA United States
- CRVO United States
- Employees
- LNZA N/A
- CRVO N/A
- Industry
- LNZA Major Chemicals
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- CRVO Health Care
- Exchange
- LNZA Nasdaq
- CRVO Nasdaq
- Market Cap
- LNZA 65.7M
- CRVO 67.4M
- IPO Year
- LNZA N/A
- CRVO N/A
- Fundamental
- Price
- LNZA $0.29
- CRVO $7.41
- Analyst Decision
- LNZA Hold
- CRVO Strong Buy
- Analyst Count
- LNZA 2
- CRVO 7
- Target Price
- LNZA $2.00
- CRVO $19.33
- AVG Volume (30 Days)
- LNZA 1.8M
- CRVO 168.7K
- Earning Date
- LNZA 08-07-2025
- CRVO 08-08-2025
- Dividend Yield
- LNZA N/A
- CRVO N/A
- EPS Growth
- LNZA N/A
- CRVO N/A
- EPS
- LNZA N/A
- CRVO N/A
- Revenue
- LNZA $48,831,000.00
- CRVO $9,308,215.00
- Revenue This Year
- LNZA $58.17
- CRVO N/A
- Revenue Next Year
- LNZA $10.92
- CRVO N/A
- P/E Ratio
- LNZA N/A
- CRVO N/A
- Revenue Growth
- LNZA N/A
- CRVO 15.14
- 52 Week Low
- LNZA $0.14
- CRVO $1.80
- 52 Week High
- LNZA $2.74
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- LNZA 52.65
- CRVO 55.27
- Support Level
- LNZA $0.27
- CRVO $5.45
- Resistance Level
- LNZA $0.31
- CRVO $8.20
- Average True Range (ATR)
- LNZA 0.03
- CRVO 0.57
- MACD
- LNZA -0.00
- CRVO 0.20
- Stochastic Oscillator
- LNZA 69.74
- CRVO 71.27
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.